Compare Apartment Investment and Management Co (AIV) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apartment Investment and Management Co vs Cytokinetics Inc — how do they compare? Apartment Investment and Management Co trades at $2.91 (market cap $422.94M), while Cytokinetics Inc trades at $83.21 (market cap $11.62B). The key difference: Cytokinetics Inc is far larger — about 27.5× Apartment Investment and Management Co's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | CYTK | |
|---|---|---|
Market Cap | $422.94M | $11.62B |
Sector | Real Estate | Technology |
52-Week High | $8.76 | $87.26 |
52-Week Low | $2.87 | $33.23 |
Enterprise Value | $669.06M | $12.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
